Tekturna® (or the generic form aliskiren) is prescribed to treat hypertension, or high blood pressure, alone or combined with other medications. It falls in a class of drugs known as direct rennin inhibitors, and it works by decreasing certain natural chemicals that tighten the blood vessels, enabling the blood vessels to relax and the heart to pump blood more efficiently.
Aliskiren, though approved by the FDA to treat hypertension, may be used to treat other conditions. Other forms of the medication may include Rasilez®, Rasilez HCT®/Tekturna HCT®, Valturna®, Rasilamlo®/Tekamlo®, and Rasitrio®/Amturnide®.
For a free legal consultation, call 800-285-4878
Recently, a study conducted by Novartis, the drug’s manufacturer, revealed patients suffering from Type-2 diabetes who were treated with Tekturna® were found to be more likely to suffer non-fatal stroke, kidney injury, high potassium, and low blood pressure than Type-2 diabetics who were not treated with the drug. In December of 2011, Novartis announced the early termination of its ALTITUDE trial due to the fact that patients within the study population were found to suffer these serious side effects at high rates. The study included over 8,600 patients from 36 different countries.
It is important that anyone taking the drug Tekturna® consult their physician. Do not alter any dosage or halt any of your current medications without consulting your physician first.
If you or a loved one used Tekturna and suffered stroke, kidney injury, low blood pressure, or high potassium or death, contact my office as soon as possible to speak with a member of my staff to determine your legal rights. Call or use the form on this page to contact us immediately.